Illumina Acquires Fluent BioSciences To Advance Single cell Analysis

India Pharma Outlook Team | Thursday, 11 July 2024

 biotechnology firm, single-cell technology, India Pharma Outlook

Illumina, a US based biotechnology firm, declared that it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent's single-cell examination innovation takes out the requirement for intricate, costly instrumentation and microfluidic consumables. 

Single-cell analysis is now accessible to a wider range of customers and also catalyzes new experiments made possible by the ability to perform that assay at the time of sample collection. The most recent version of Fluent, PIPseq V, offers exceptional performance, the highest scalability, and the capacity to process anything from 100 cells to 1 million with the ability to identify cell types that are frequently missed by other approaches.

"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."

Customers will receive a complete solution and a single point of support from both biotechnology firms leading sequencing and informatics solutions, including Partek Flow, which enables single-cell multiomic analysis. This will enable researchers to advance discovery faster and at a lower cost. The Fluent team will join Illumina, and PIPseq V will be integrated into Illumina's product portfolio. The company intends to develop complete, end-to-end solutions for single-cell analysis based on the technology of Fluent.

© 2024 India Pharma Outlook. All Rights Reserved.